(919) 237-4897 info@t3dtherapeutics.com

News + Events

Stay up to date with our latest news

T3D Therapeutics Reports Successful Pre-IND Meeting with the FDA

T3D Therapeutics announced today that it had a successful Type B Pre-Investigational New Drug (“Pre-IND) meeting on April 1st with the US Food and Drug Administration’s Division of Neurology Products, for T3D-959, a novel nuclear receptor agonist for the treatment of...